Ambulatory COVID-19 Patients Benefit from Neutralizing Antibody Cocktail
Brii Biosciences announced today that its monoclonal antibody combination therapy, BRII-196 and BRII-198, non-competing SARS-CoV-2 neutralizing antibodies derived from convalesced COVID-19 patients, met pre-specified safety and efficacy criteria, permitting the continuation of Phase 3 of the ACTIV-2 trial.
These neutralizing antibodies have been specifically engineered to reduce the risk of antibody-dependent enhancement and prolong the plasma half-lives for potentially more durable treatment effects. Their non-overlapping epitope binding regions provide a high degree of neutralization activity against SARS-CoV-2, with preliminary in vitro evidence suggesting continued antiviral activity against commonly circulating variants from the U.K. and South Africa.
Zhi Hong, Ph.D., CEO of Brii Bio, stated in a press release issued on April 29, 2021, “As BRII-196 and BRII-198 are the first to progress to Phase 3 evaluation in the ACTIV-2 trial, we look forward to adding international trial sites to this study, which is especially critical for regions experiencing a surge in COVID-19 cases and new variants.”
With operations in the People's Republic of China and the United States, Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases and CNS diseases.